# Correction: Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

**Authors:** Álvaro Rodríguez-Lescure, Javier Gallego, Pilar Garcia-Alfonso, Bartomeu Massuti, Raúl Márquez, Lourdes Calvo, Pedro Sánchez-Rovira, Antonio Antón, José Ignacio Chacón, Eva Ciruelos, Jose Juan Ponce, Ana Santaballa, Manuel Valladares-Ayerbes, María Rosario Dueñas, Vicente Alonso, Jorge Aparicio, Sara Encinas, Luis Robles, María José Escudero, Rosalía Caballero, Susana Bezares, María Victoria García-Ortiz, Teresa Morales-Ruiz, Juan de la Haba-Rodriguez

PMC · DOI: 10.1007/s12094-025-04113-7 · Clinical & Translational Oncology · 2025-11-25

## Full-text entities

- **Diseases:** breast and colorectal cancer (MESH:D001943), Hypertension (MESH:D006973)
- **Chemicals:** bevacizumab (MESH:D000068258)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12790484/full.md

---
Source: https://tomesphere.com/paper/PMC12790484